Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Management of Diuretic Refractory Ascites in Cirrhosis With Empagliflozin (DRAin-Em-01)

NCT05013502 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT05013502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05013502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Management of Diuretic Refractory Ascites in Cirrhosis With Empagliflozin (DRAin-Em-01)
Lead sponsor
Stanford University
Phase
Phase 1
Overall status
Completed
Start date
November 15, 2021
Completion date
June 30, 2023
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ascites, ascites hepatic, cirrhosis, liver cirrhosis, sodium-glucose transporter 2 inhibitors